Healthy people
Conditions
Interventions
None listed
Sponsors
Biogen Japan Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Mentally healthy subjects without any neurological, psychiatric, or developmental disorders 2.Subjects aged >= 20 years and <= 65 years 3.Subjects who provide written consent form to participate in this study after full explanation of the study. Minor subjects need additional written consent form signed by legal representative 4.Subjects who can communicate in Japanese 5.Subjects who had not conducted iPad-based PST test previously 6.Male and female
Exclusion criteria
Exclusion criteria: 1.Subjects who have treated for or have history of any of following disease motor tic or vocal tic (including diagnosis of Tourette syndrome), head trauma with severe unconsciousness (more than 30 min), stroke (including ischemic and hemorrhagic stroke or transient ischemic attack (TIA)), neurological, developmental, medical, or conditional arterial disease including that in carotid artery, cerebral palsy, epilepsy, brain tumor, dementia (including mild cognitive disorder and Alzheimer's disease), chronic meningitis, multiple sclerosis, pernicious anemia, normal pressure hydrocephalus, HIV infection, Parkinson's disease, Huntington's disease, learning disability, attention deficit disorder, untreated hypertension (160/100 mmHg), severe cardiac disease, insulin-dependent diabetes mellitus, endocrine disorder, renal disease, glaucoma, or chronic obstructive pulmonary disease 2.Subjects with psychiatric disorder diagnosed by DSM-V criteria 3. Subjects with history of drug abuse and alcohol dependence syndrome 4. Subjects who are treated by currently prescribed psychotropic drugs for psychotic disorder, epilepsy, chronic sedative drug/hypnotic or narcotic analgesic (selective serotonin reuptake inhibitors (SSRI) and serotonin & norepinephrine reuptake inhibitors (SNRI) are permitted) 5. Subjects who are treated by any of following drugs which are expected to affect cognitive function Adderall, Ritalin(methylphenidate), TOPINA(topiramate), EXELON(rivastigmine tartrate), ARICEPT(donepezil hydrochloride), specific analgesic drug such as oxycodone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of PST score | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Distribution of PST scores stratified by educational status 2.Distribution of PST scores stratified by age 3.Distribution of PST scores stratified by gender | — |
Countries
Japan
Contacts
Public ContactTatsuya Hayashi
PPD-SNBL Department of Clinical Development
Outcome results
None listed